The first Antibody-drug conjugate (ADC) was approved overa quarter-century ago, and today more than 20 have reached the clinic.

And this one-on-one battle could offer insights about how two of the hottest drug categories in oncology — ADCs and ...

At ASCO 2026 in Chicago, Pedro Valencia, vice president of asset strategy leadership for oncology at AbbVie, joined ...

At the year’s biggest cancer meeting, a high-stakes clash between two popular drug classes erupted, and scientists made ...

The recent acquisition of ImmunoGen by AbbVie, which followed the earlier acquisition of Seagen by Pfizer, has brought renewed attention to antibody-drug conjugates (ADCs), highlighting their ...

Lonza and Antharis Therapeutics, Inc., a biopharmaceutical company developing next-generation antibody-based therapeutics for ...

MADRID — If you had to pinpoint one subject that stood out at this year’s European Society for Medical Oncology meeting, a massive conference with thousands of people from 140-some countries and 2,500 ...

Dr. Paolo Tarantino shares how antibody-drug conjugates deliver more targeted chemo, and how the treatment lasts longer in the body vs traditional therapy. Antibody-drug conjugates (ADCs) are changing ...

Antibody Drug Conjugates (ADCs) are a class of small molecule drugs (also known as a payload) and an antibody conjugated together by a chemical linker. ADCs are designed to target specific cells, such ...

VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today announced that the Company has generated new in vitro proof-of-concept data validating its ...